Trial Profile
A compassionate use programme assessing the efficacy and safety of Venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post Bruton tyrosine kinase inhibition therapy
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 27 Jul 2018
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 27 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association